Biodesix Launches COVID-19 WorkSafe™ Employer Testing Program

Range of Testing Solutions Aimed at Helping Businesses Safely Resume Work Operations

BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc., a leading diagnostic company in lung disease, announced today that it has launched the Biodesix WorkSafe™ Program, a customized return to work service for employers. The program is designed to help all businesses in the U.S. and incorporates two highly-accurate diagnostic tests for COVID-19 with an end-to-end customized solution to assist companies in their goals of preventing and slowing the spread of COVID-19 while resuming business operations. Results for both tests are provided in 24 hours after the sample is received at the Biodesix Laboratory.

“Our advanced expertise, laboratory qualifications, and diagnostic technologies, which have been years in the making, have positioned Biodesix to be a hub for coronavirus testing solutions,” said Scott Hutton, CEO of Biodesix. “In offering options through a number of testing services, we hope to minimize the risk of increasing COVID-19 infection rates due to businesses reopening, and to offer valuable information to employees and their employers that can support informed decision-making.”

Biodesix has commercialized two tests developed by Bio-Rad Laboratories, Inc. for COVID-19 detection: the SARS-CoV-2 ddPCR Test (molecular) and the Platelia SARS-CoV-2 Total Ab Test (antibody). The molecular test diagnoses active COVID-19 infection with high accuracy and uses a nasopharyngeal swab to collect the sample. The molecular test can be used to identify patients who should quarantine and should not yet return to work. The antibody test identifies patients who may have previously been infected by COVID-19. When tested more than eight days following the onset of symptoms, the test achieves 97.50% sensitivity and 99.56% specificity using a simple blood draw. This test identifies patients who may have developed some level of immunity against the virus.

More information is available at https://www.biodesix.com/products/covid-testing-employers.

About Biodesix

Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood-based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood-based Nodify Lung™ nodule risk assessment testing strategy consisting of the Nodify XL2™ test and the Nodify CDT™ test evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, please visit www.biodesix.com.

Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, Biodesix operates in a competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for its management to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.

Contacts

Jordona Jackson Smith for Biodesix

[email protected]
(805) 674-7347